Has inhibition of Aβ production adequately been tested as therapeutic approach in mild AD? A model-based meta-analysis of γ-secretase inhibitor data

European Journal of Clinical Pharmacology

Volumn 69, Issue 6, 2013, Pages 1247-1260

  Niva, Camilla ^a   Parkinson, Joanna ^a   Olsson, Fredrik ^a   Van Schaick, Erno ^b   Lundkvist, Johan ^a   Visser, Sandra A G ^a  

^a ASTRAZENECA R AND D   (Sweden)

^b Exprimo NV   (Belgium)

Author keywords

secretase inhibitors (semagacestat, Avagacestat, Begacestat, PF 3074014 and MK0752); A ; Alzheimer's disease; Modeling; Translation

Indexed keywords

AMYLOID A PROTEIN; AMYLOID BETA PROTEIN; AVAGACESTAT; BEGACESTAT; GAMMA SECRETASE INHIBITOR; MK 0752; PF 3074014; SEMAGACESTAT; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANIMAL TISSUE; ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EXPOSURE; DRUG MECHANISM; ENZYME INHIBITION; FEMALE; GUINEA PIG; HUMAN; IN VIVO STUDY; MALE; META ANALYSIS; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; BRAIN; COGNITION; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; DRUG EVALUATION, PRECLINICAL; ENZYME INHIBITORS; HUMANS; MODELS, BIOLOGICAL; SPECIES SPECIFICITY; TREATMENT OUTCOME;

EID: 84878012448     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/s00228-012-1459-3     Document Type: Article

References (49)

1. Alzheimer's Association (2012) 2012 Alzheimer's disease facts and figures. Alzheimer Dement 8:131-168
2. D'Onofrio G, Panza F, Frisardi V, Solfrizzi V, Imbimbo BP, Paroni G, Cascavilla L, Seripa D, Pilotto A (2012) Advances in the identification of gamma-secretase inhibitors for the treatment of Alzheimer's disease. Expert Opin Drug Discov 7:19-37
3. Golde TE, Schneider LS, Koo EH (2011) Anti-abeta therapeutics in Alzheimer's disease: the need for a paradigm shift. Neuron 69:203-213
4. Panza F, Frisardi V, Imbimbo BP, Capurso C, Logroscino G, Sancarlo D, Seripa D, Vendemiale G, Pilotto A, Solfrizzi V (2010) Review: gamma-Secretase inhibitors for the treatment of Alzheimer's disease: the current state. CNS Neurosci Ther 16:272-284
5. Hardy J (2009) The amyloid hypothesis for Alzheimer's disease: a critical reappraisal. J Neurochem 110:1129-1134
6. Karran E, Mercken M, De Strooper B (2011) The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics. Nat Rev Drug Discov 10:698-712
7. Wolfe MS (2012) gamma-Secretase inhibitors and modulators for Alzheimer's disease. J Neurochem 120 [Suppl 1]:89-98
8. Walsh DM, Teplow DB (2012) Alzheimer's disease and the amyloid beta-protein. Prog Mol Biol Transl Sci 107:101-124
9. Lichtenthaler SF, Haass C, Steiner H (2011) Regulated intramembrane proteolysis - lessons from amyloid precursor protein processing. J Neurochem 117:779-796
10. Citron M (2010) Alzheimer's disease: strategies for disease modification. Nat Rev Drug Discov 9:387-398
11. Kreft AF, Martone R, Porte A (2009) Recent advances in the identification of gamma-secretase inhibitors to clinically test the Abeta oligomer hypothesis of Alzheimer's disease. J Med Chem 52:6169-6188
12. Burton CR, Meredith JE, Barten DM, Goldstein ME, Krause CM, Kieras CJ, Sisk L, Iben LG, Polson C, Thompson MW, Lin XA, Corsa J, Fiedler T, Pierdomenico M, Cao Y, Roach AH, Cantone JL, Ford MJ, Drexler DM, Olson RE, Yang MG, Bergstrom CP, McElhone KE, Bronson JJ, Macor JE, Blat Y, Grafstrom RH, Stern AM, Seiffert DA, Zaczek R, Albright CF, Toyn JH (2008) The amyloid-beta rise and gamma-secretase inhibitor potency depend on the level of substrate expression. J Biol Chem 283:22992-23003
13. Jamsa A, Belda O, Edlund M, Lindstrom E (2011) BACE-1 inhibition prevents the gamma-secretase inhibitor evoked Abeta rise in human neuroblastoma SH-SY5Y cells. J Biomed Sci 18:76
14. Lanz TA, Karmilowicz MJ, Wood KM, Pozdnyakov N, Du P, Piotrowski MA, Brown TM, Nolan CE, Richter KE, Finley JE, Fei Q, Ebbinghaus CF, Chen YL, Spracklin DK, Tate B, Geoghegan KF, Lau LF, Auperin DD, Schachter JB (2006) Concentration-dependent modulation of amyloid-beta in vivo and in vitro using the gamma-secretase inhibitor, LY-450139. J Pharmacol Exp Ther 319:924-933
15. Kumamoto M, Nakano M, Uenaka K, Lowe S, Nishiuma S, Nakamichi N, Dean R, Siemers E, Mohs R (2008) P4-379: safety, tolerability, pharmacokinetics and pharmacodynamics of multiple-dose administration of a gamma-secretase inhibitor in Japanese subjects. Alzheimer Dement 4:T785
16. Siemers ER, Dean RA, Friedrich S, Ferguson-Sells L, Gonzales C, Farlow MR, May PC (2007) Safety, tolerability, and effects on plasma and cerebrospinal fluid amyloid-beta after inhibition of gamma-secretase. Clin Neuropharmacol 30:317-325
17. Tong G, Wang JS, Sverdlov O, Huang SP, Slemmon R, Croop R, Castaneda L, Gu H, Wong O, Li H, Berman RM, Smith C, Albright CF, Dockens RC (2012) Multicenter, randomized, double-blind, placebo-controlled, single-ascending dose study of the oral gamma-secretase inhibitor BMS-708163 (avagacestat): tolerability profile, pharmacokinetic parameters, and pharmacodynamic markers. Clin Ther 34:654-667
18. Martone RL, Zhou H, Atchison K, Comery T, Xu JZ, Huang X, Gong X, Jin M, Kreft A, Harrison B, Mayer SC, Aschmies S, Gonzales C, Zaleska MM, Riddell DR, Wagner E, Lu P, Sun SC, Sonnenberg-Reines J, Oganesian A, Adkins K, Leach MW, Clarke DW, Huryn D, Abou-Gharbia M, Magolda R, Bard J, Frick G, Raje S, Forlow SB, Balliet C, Burczynski ME, Reinhart PH, Wan HI, Pangalos MN, Jacobsen JS (2009) Begacestat (GSI-953): a novel, selective thiophene sulfonamide inhibitor of amyloid precursor protein gamma-secretase for the treatment of Alzheimer's disease. J Pharmacol Exp Ther 331:598-608
19. Frick G, Raje S, Wan H, Forlow SB, Balliet C, Pastore A, Burczynski ME, Jhee S, Ereshefsky L, Paul J (2008) P4-366: GSI-953, a potent and selective gamma-secretase inhibitor: modulation of beta-amyloid peptides and plasma and cerebrospinal fluid pharmacokinetic/pharmacodynamic relationships in humans. Alzheimer Dement 4:T781
20. Tai LM, Jacobsen H, Ozmen L, Flohr A, Jakob-Roetne R, Caruso A, Grimm HP (2012) The dynamics of Abeta distribution after gamma-secretase inhibitor treatment, as determined by experimental and modelling approaches in a wild type rat. J Pharmacokinet Pharmacodyn 39:227-237
21. Lu Y, Riddell D, Hajos-Korcsok E, Bales K, Wood KM, Nolan CE, Robshaw AE, Zhang L, Leung L, Becker SL, Tseng E, Barricklow J, Miller EH, Osgood S, O'Neill BT, Brodney MA, Johnson DS, Pettersson M (2012) CSF Abeta as an effect biomarker for brain Abeta lowering verified by quantitative preclinical analyses. J Pharmacol Exp Ther 342:366-375
22. Lu Y, Zhang L, Nolan CE, Becker SL, Atchison K, Robshaw AE, Pustilnik LR, Osgood SM, Miller EH, Stepan AF, Subramanyam C, Efremov I, Hallgren AJ, Riddell D (2011) Quantitative pharmacokinetic/pharmacodynamic analyses suggest that the 129/SVE mouse is a suitable preclinical pharmacology model for identifying small-molecule gamma-secretase inhibitors. J Pharmacol Exp Ther 339:922-934
23. Fleisher AS, Raman R, Siemers ER, Becerra L, Clark CM, Dean RA, Farlow MR, Galvin JE, Peskind ER, Quinn JF, Sherzai A, Sowell BB, Aisen PS, Thal LJ (2008) Phase 2 safety trial targeting amyloid beta production with a gamma-secretase inhibitor in Alzheimer disease. Arch Neurol 65:1031-1038
24. Bateman RJ, Siemers ER, Mawuenyega KG, Wen G, Browning KR, Sigurdson WC, Yarasheski KE, Friedrich SW, Demattos RB, May PC, Paul SM, Holtzman DM (2009) A gamma-secretase inhibitor decreases amyloid-beta production in the central nervous system. Ann Neurol 66:48-54
25. Wang J, Castaneda L, Sverdlov A, Huang S, Slemmon R, Gu H, Wong O, Li H, Berman RM, Smith C, Albright CF, Dockens R, Tong G, Arroyo S (2010) A placebo-controlled, ascending, multiple-dose study to evaluate the safety, pharmacokinetics (PK) and pharmacodynamics (PD) of BMS-708163 in healthy young and elderly subjects. Alzheimer Dement 6:S540
26. Meredith J, Albright CF, Dockens RC, Olson RE, Lentz KA, Wang JS, Denton RR, Pilcher G, Zaczek R, Macor JE, Houston J, Wong O, Gu H, Berman RM, Tong G (2011) BMS-708163, a Notch-sparing GSI, decreases central Aβ in rats, dogs, and humans with a therapeutic margin relative to Notch toxicity
27. Tong G, Wang JS, Sverdlov O, Huang SP, Slemmon R, Croop R, Castaneda L, Wu H, Wong O, Li H, Berman RM, Smith C, Albright CF, Dockens R (2012) A contrast in safety, pharmacokinetics, and pharmacodynamics across age groups after a single 50-mg oral dose of the gamma-secretase inhibitor avagacestat. Br J Clin Pharmacol doi: 10.1111/j.1365-2125.2012.04339.x
28. Wan H, Bard J, Martone R, Rage S, Forlow S, Kreft A, Jacobsen S, Silver P, Paul J, Frick G (2008) P3-101: GSI-953, a potent and selective gamma-secretase inhibitor, modulates Abeta peptides in mice and humans: translating the PK/PD biomarker relationships in different biological compartments between rodent and human. Alzheimer Dement 4:T548
29. 2 in humans after multiple oral doses of PF-3084014, a potent gamma-secretase inhibitor. Alzheimer Dement 5:P253
30. Soares H, Raha N, Sikpi M, Liston D, Brodney M, Coffman K, Tate B, Qiu R, Wang EQ, Li X, Hidi R, Banerjee S, Jhee S, Ereshefsky L, Fullerton T (2009) Aβ variability and effect of gamma secretase inhibition on cerebrospinal fluid levels of Aβ in healthy volunteers. Alzheimer Dement 5:P252-P253
31. Lanz TA, Wood KM, Richter KE, Nolan CE, Becker SL, Pozdnyakov N, Martin BA, Du P, Oborski CE, Wood DE, Brown TM, Finley JE, Sokolowski SA, Hicks CD, Coffman KJ, Geoghegan KF, Brodney MA, Liston D, Tate B (2010) Pharmacodynamics and pharmacokinetics of the gamma-secretase inhibitor PF-3084014. J Pharmacol Exp Ther 334:269-277
32. Das R, Nachbar RB, Edelstein-Keshet L, Saltzman JS, Wiener MC, Bagchi A, Bailey J, Coombs D, Simon AJ, Hargreaves RJ, Cook JJ (2010) Modeling effect of a gamma-secretase inhibitor on amyloid-beta dynamics reveals significant role of an amyloid clearance mechanism. Bull Math Biol 73:230-247
33. Cook JJ, Wildsmith KR, Gilberto DB, Holahan MA, Kinney GG, Mathers PD, Michener MS, Price EA, Shearman MS, Simon AJ, Wang JX, Wu G, Yarasheski KE, Bateman RJ (2010) Acute gamma-secretase inhibition of nonhuman primate CNS shifts amyloid precursor protein (APP) metabolism from amyloid-beta production to alternative APP fragments without amyloid-beta rebound. J Neurosci 30:6743-6750
34. Ereshefsky L, et al. (2008) Demonstrating proof of principle in Alzheimers disease: the role of CSF 'dynabridging' studies. Society for CNS Clinical trials and Methodology
35. Stone J (2009) Modeling of Ab dynamics in animals and humans. American Society for Clinical Pharmacology and Therapeutics (ASCPT) Annual Meeting
36. Rosen LB, Stone JA, Plump A, Yuan J, Harrison T, Flynn M, Dallob A, Matthews C, Stevenson D, Schmidt D, Palmieri T, Leibowitz M, Jhee S, Ereshefsky L, Salomon R, Winchell G, Shearman MS, Murphy MG, Gottesdiener KM (2006) O4-03-02: the gamma secretase inhibitor MK-0752 acutely and significantly reduces CSF Abeta40 concentrations in humans. Alzheimer Dement 2:S79
37. Jusko WJ, Ko HC (1994) Physiologic indirect response models characterize diverse types of pharmacodynamic effects. Clin Pharmacol Ther 56:406-419
38. Beal SL, Sheiner LB, Boeckmann AJ, Bauer RJ (1989-2009) NONMEM Users Guides
39. Siemers E, Skinner M, Dean RA, Gonzales C, Satterwhite J, Farlow M, Ness D, May PC (2005) Safety, tolerability, and changes in amyloid beta concentrations after administration of a gamma-secretase inhibitor in volunteers. Clin Neuropharmacol 28:126-132
40. Li J, Llano DA, Ellis T, Leblond D, Bhathena A, Jhee SS, Ereshefsky L, Lenz R, Waring JF (2011) Effect of human cerebrospinal fluid sampling frequency on amyloid-beta levels. Alzheimers Dement 8:295-303
41. Gillman KW, Starrett JE, Parker MF, Xie K, Bronson JJ, Marcin LR, McElhone KE, Bergstrom CP, Mate RA, Williams R, Meredith JE, Burton CR, Barten DM, Toyn JH, Roberts SB, Lentz KA, Houston JG, Zaczek R, Albright CF, Decicco CP, Macor JE, Olson RE (2010) Discovery and evaluation of BMS-708163, a potent, selective and orally bioavailable γ-secretase inhibitor. ACS Med Chem Lett 1:120-124
42. Portelius E, Van Broeck B, Andreasson U, Gustavsson MK, Mercken M, Zetterberg H, Borghys H, Blennow K (2010) Acute effect on the Abeta isoform pattern in CSF in response to gamma-secretase modulator and inhibitor treatment in dogs. J Alzheimer Dis 21:1005-1012
43. Janson J, Eketjäll S, Yan H, Tunblad K, Jeppsson F, Briem S, Dahlqvist C, Radesäter AC, Fälting J, Visser SAG (2012) Population PKPD modeling of BACE1 inhibitors induced reduction in brain Aβ levels in vivo
44. Morgan P, Van Der Graaf PH, Arrowsmith J, Feltner DE, Drummond KS, Wegner CD, Street SD (2012) Can the flow of medicines be improved? Fundamental pharmacokinetic and pharmacological principles toward improving Phase II survival. Drug Discov Today 17:419-424
45. Doody RS, Cole PE, Miller DS, Siemers E, Black R, Feldman H, Schindler R, Graham S, Heath T, Khachaturian AS, Evans R, Carrillo MC (2011) Global issues in drug development for Alzheimer's disease. Alzheimer Dement 7:197-207
46. Abramowski D, Wiederhold KH, Furrer U, Jaton AL, Neuenschwander A, Runser MJ, Danner S, Reichwald J, Ammaturo D, Staab D, Stoeckli M, Rueeger H, Neumann U, Staufenbiel M (2008) Dynamics of Abeta turnover and deposition in different beta-amyloid precursor protein transgenic mouse models following gamma-secretase inhibition. J Pharmacol Exp Ther 327:411-424
47. Dutta S, Ebling WF (1997) Parameter estimability of biphasic response models. J Pharm Sci 86:44-51
48. Li T, Huang Y, Jin S, Ye L, Rong N, Yang X, Ding Y, Cheng Z, Zhang J, Wan Z, Harrison DC, Hussain I, Hall A, Lee DHS, Lau L, Matsuoka Y (2012) Secretase modulators do not induce Aβ-rebound and accumulation of β-C-terminal fragment. J Neurochem 121:277-286
49. Ortega F, Stott J, Visser SAG, Bendtsen C (2012) Interplay between α, β and γ-secretases determines biphasic Aβ levels in the presence of a γ-secretases inhibitor. J Biol Chem doi: 10.1074/jbc.M112.419135